![Tiba Aynechi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tiba Aynechi
Director/Board Member at
MBX BIOSCIENCES, INC.
Net worth: - $ as of 2026-06-29
Profile
Tiba Aynechi is currently Director at Engrail Therapeutics, Inc. since 2024, Director at Nuvig Therapeutics, Inc. since 2024, Director at Ray Therapeutics, Inc. since 2023, Director at Rezo Therapeutics, Inc. since 2022, Director at Avalyn Pharma, Inc. since 2017, Independent Director at MBX Biosciences, Inc. since 2022, and General Partner at Norwest Venture Partners since 2021.
Former roles include Director at Arcellx, Inc. from 2015 to 2021, Director at HTG Molecular Diagnostics, Inc. from 2011 to 2015, Director at AnaptysBio, Inc. from 2015 to 2017, Director at iRhythm Holdings, Inc. from 2014 to 2017, Director at Thesan Pharmaceuticals, Inc. from 2012 to 2014, Director at Nevro Corp.
from 2013 to 2014, Director at Cianna Medical, Inc. from 2011 to 2018, Director at Otonomy, Inc. from 2010 to 2014, Director at Rainier Therapeutics, Inc. from 2014 to 2015, Director at MDLIVE, Inc. from 2018 to 2021, Independent Director at Mirum Pharmaceuticals, Inc. from 2018 to 2021, Director at Aristea Therapeutics, Inc. from 2018 to 2021, Independent Director at Spruce Biosciences, Inc. from 2016 to 2025, Director at Allievex Corp., Independent Director at Nkarta, Inc. from 2015 to 2022, Senior Associate at Burrill LLC from 2006 to 2009, Senior Partner at Novo Ventures (US), Inc. from 2010 to 2021, Senior Partner at Novo Holdings A from 2010 to 2021, and Senior Partner at Novo Ventures 1 A from 2010 to 2021.
Education includes an undergraduate degree from the University of California, Irvine in 1998 and a doctorate from The University of California, San Francisco in 2004.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-07-21 | 0 ( -.--% ) | - $ | 2026-06-29 | |
| 2026-06-03 | 0 ( -.--% ) | - $ | 2026-06-29 |
Tiba Aynechi active positions
| Companies | Position | Start |
|---|---|---|
| AVALYN PHARMA INC. | Director/Board Member | 2017-02-28 |
| MBX BIOSCIENCES, INC. | Director/Board Member | 2022-11-30 |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops translating novel therapeutics medicine for autoimmune diseases | Director/Board Member | 2024-11-30 |
Engrail Therapeutics, Inc.
 Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for treating neuron diseases | Director/Board Member | 2024-04-30 |
Ray Therapeutics, Inc.
 Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops optogenetic gene therapies for patients with blinding diseases | Director/Board Member | 2023-04-30 |
Rezo Therapeutics, Inc.
 Rezo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence | Director/Board Member | 2022-06-30 |
Norwest Venture Partners
 Norwest Venture Partners Investment ManagersFinance Norwest Venture Partners invests in companies located in North America, India and Israel. The firm focuses on companies operating across a broad range of sectors and industries.It participates in early and later stage transactions with an investment size of USD 10 - 100 million. | Private Equity Investor | 2021-11-30 |
Former positions of Tiba Aynechi
| Companies | Position | End |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Director/Board Member | 2025-12-10 |
| NKARTA, INC. | Director/Board Member | 2022-05-31 |
| ░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░ ░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Tiba Aynechi
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
62
1st degree connections
28
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 28 |
|---|---|
HTG Molecular Diagnostics, Inc.
 HTG Molecular Diagnostics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides molecular technology solutions | Commercial Services |
AnaptysBio, Inc.
 AnaptysBio, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
iRhythm Technologies, Inc.
 iRhythm Technologies, Inc. Medical SpecialtiesHealth Technology Provides monitoring and diagnostic solutions for detection of cardiac arrhythmias | Health Technology |
Thesan Pharmaceuticals, Inc.
 Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces novel therapeutics for skin disorders | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Finance |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Norwest Venture Partners
Norwest Venture Partners Investment ManagersFinance Norwest Venture Partners invests in companies located in North America, India and Israel. The firm focuses on companies operating across a broad range of sectors and industries.It participates in early and later stage transactions with an investment size of USD 10 - 100 million. | Finance |
Nevro Corp.
 Nevro Corp. Medical SpecialtiesHealth Technology Operates as a medical device company | Health Technology |
Cianna Medical, Inc.
 Cianna Medical, Inc. Medical SpecialtiesHealth Technology Manufactures and designs medical products for treatment of early-stage breast cancer in women | Health Technology |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Finance |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurology diseases | Health Technology |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world. | Finance |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Health Technology |
MDLIVE, Inc.
 MDLIVE, Inc. Medical/Nursing ServicesHealth Services Provides health care by phone and video | Health Services |
Arcellx, Inc.
 Arcellx, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies | Health Technology |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company which develops novel therapies for endocrine diseases | Health Technology |
Nkarta, Inc.
 Nkarta, Inc. BiotechnologyHealth Technology Discovers, develops and delivers NK cell therapies for cancer treatment | Health Technology |
Mirum Pharmaceuticals, Inc.
 Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
Aristea Therapeutics, Inc.
 Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies to treat serious inflammatory diseases | Health Technology |
MBX Biosciences, Inc.
 MBX Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on discovery and development of novel precision peptide therapies for endocrine & metabolic disorders | Health Technology |
Allievex Corp.
 Allievex Corp. Pharmaceuticals: OtherHealth Technology Develops and manufactures novel therapies for the treatment of rare pediatric neurodegenerative diseases | Health Technology |
Engrail Therapeutics, Inc.
Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for treating neuron diseases | Health Technology |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops optogenetic gene therapies for patients with blinding diseases | Commercial Services |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops translating novel therapeutics medicine for autoimmune diseases | Health Technology |
Rezo Therapeutics, Inc.
Rezo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence | Commercial Services |
- Stock Market
- Insiders
- Tiba Aynechi
Choose MarketScreener 
